KDM4A and prostate carcinoma: Although it was capable of inhibiting KDM4's with an association for KDM4A (IC50 = 6.4 μM) and KDM4B (IC50 = 9.3 μM) it was not as potent as other inhibitors published at the time (namely JIB-04) (157) and in a prostate cancer model has a reduced inhibitory concentration of 16.5 μM showing a reduced cell permeability and specificity.